The Company has more than 45 proprietary and partnered product candidates in development
Ablynx participates and presents at IR and scientific conferences
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
ABLYNX ACHIEVES FIRST MILESTONE AS PART OF COLLABORATION WITH NOVO NORDISK30 November 2016
ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2016 AND A YEAR-TO-DATE BUSINESS UPDATE23 November 2016
FMR LLC ANNOUNCE 9.10% SHAREHOLDING IN ABLYNX18 November 2016
TITAN study - Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura